Get the Stockscreener App
0.70
5.02%
-0.037
After Hours:
.70
Pasithea Therapeutics Corp stock is traded at $0.70, with a volume of 294.00K.
It is down -5.02% in the last 24 hours and down -22.65% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.737
Open:
$0.718
24h Volume:
294.00K
Relative Volume:
0.04
Market Cap:
$16.16M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0503
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-8.10%
1M Performance:
-22.65%
6M Performance:
+0.00%
1Y Performance:
-51.05%
1-Day Range:
$0.6819
$0.7403
1-Week Range:
$0.6819
$0.7834
52-Week Range:
$0.281
$3.79
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.70 | 17.02M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Aug PreEarnings: Why Pasithea Therapeutics Corp. Equity Warrant stock could be next big winnerTrade Analysis Summary & AI Enhanced Trade Execution Alerts - mfd.ru
Earnings Miss: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly pricedJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Dividend Watch: What is the Moat Score of Pasithea Therapeutics Corp Equity WarrantGDP Growth & Stock Market Timing Techniques - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Levels: Can Pasithea Therapeutics Corp disrupt its industryWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Meme Stocks: Can Beyond Meat Inc. navigate macro headwindsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Jobs Data: What is the long term forecast for Pasithea Therapeutics Corp stockJuly 2025 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Weekly Earnings: Can Pasithea Therapeutics Corp disrupt its industryQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Institution Moves: Can Alerus Financial Corporation withstand a market correctionBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Pasithea Therapeutics Corp. stock influenced by commodity prices2025 Historical Comparison & Consistent Profit Trading Strategies - Mfd.ru
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization - TipRanks
Fundamentals Check: Is POET benefiting from innovation trends2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Performance Recap: Should I average down on WRAP stockMarket Movers & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aug Shorts: Can Pasithea Therapeutics Corp sustain earnings growth2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
How does SWVL compare to its peersEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Published on: 2026-01-22 13:20:30 - baoquankhu1.vn
Aug Big Picture: Is Finward Bancorp benefiting from interest rate changes2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics regains Nasdaq compliance - MSN
New Highs: Can Pasithea Therapeutics Corp grow without external fundingJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway - TipRanks
Pasithea provides updates on clinical trials for MEK inhibitor drug By Investing.com - Investing.com Canada
Pasithea provides updates on clinical trials for MEK inhibitor drug - Investing.com
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network
Pasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced Cancer - Quiver Quantitative
Risk Hedge: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesMarket Growth Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics (NASDAQ:KTTA) Stock Rating Upgraded by Wall Street Zen - Defense World
How Pasithea Therapeutics Corp. Equity Warrant stock reacts to oil pricesJuly 2025 EndofMonth & Stepwise Trade Execution Plans - ulpravda.ru
How analysts rate Pasithea Therapeutics Corp. stock today2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why hedge funds are buying Pasithea Therapeutics Corp. stock2025 Momentum Check & Verified Swing Trading Watchlists - ulpravda.ru
What is the fair value of Pasithea Therapeutics Corp. Equity Warrant stock now2025 Bull vs Bear & Daily Growth Stock Tips - ulpravda.ru
Why Pasithea Therapeutics Corp. stock remains undervaluedJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
How Pasithea Therapeutics Corp. stock benefits from strong dollar2025 Risk Factors & Short-Term High Return Ideas - Улправда
How Pasithea Therapeutics Corp. stock compares to industry benchmarks2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
Is Pasithea Therapeutics Corp. Equity Warrant stock a dividend growth opportunity2026 world cup usa national team quarterfinals star players transition play group prediction analysis - ulpravda.ru
Will Pasithea Therapeutics Corp. Equity Warrant stock deliver shareholder value2026 world cup usa national team quarterfinals young talents transition play knockout prediction tactical review - ulpravda.ru
Pasithea Therapeutics Corp Stock Analysis and ForecastMomentum Trading Signals & Big Profit Low Capital - earlytimes.in
Is Pasithea Therapeutics Corp. overvalued or undervalued? - MarketsMojo
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Can Pasithea Therapeutics Corp. stock hit analyst price targetsWeekly Stock Analysis & Safe Entry Momentum Stock Tips - Улправда
What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock cheap at current valuationTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
Will Pasithea Therapeutics Corp. stock return to pre crisis levelsWeekly Investment Report & Fast Gaining Stock Strategy Reports - Улправда
What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stockLong Setup & Accurate Entry and Exit Point Alerts - Улправда
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):